Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Biomarker directed therapies in biliary tract cancers

James J. Harding • 5 Jun 2022
ASCO 2022
Bile Duct Cancer Gastrointestinal Cancer Infigratinib Ivosetinib Pemigatinib

Approximately 40% of biliary tract cancer harbor gene alterations that can be targeted with precision-based medicines. James J. Harding, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of the targetable mutations in biliary tract cancer and the future of the field. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from James J. Harding

1:19
A Phase I dose escalation study of BiTEs targeting P-cadherin in solid tumors
James J. Harding • 5 Jun 2022
1:20
Final results from the phase 2 SUMMIT basket trial: targeting HER2+ advanced BTCs with neratinib
James J. Harding • 5 Jun 2022
1:07
Liquid biopsies for genotyping biliary tract cancers
James J. Harding • 5 Jun 2022

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals